KeyBanc analyst Steve Dechert raised the firm’s price target on LifeStance (LFST) to $9 from $8 and keeps an Overweight rating on the shares. The firm notes the company reported a top and bottom-line beat with Q4 adjusted EBITDA 21% above consensus and clinician productivity up an impressive 7%. KeyBanc expects continued clinician productivity growth in FY26 from its new care-matching algorithm/tool as well as the rollout of its new AI clinical documentation tool.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFST:
- LifeStance spot secondary offering; price range $7.04-$7.41
- LifeStance announces 25M share offering of common stock for holders
- LifeStance price target raised to $10 from $8 at BMO Capital
- LifeStance Health: Strong Q4 Beat, Productivity Gains, and Differentiated Clicks-and-Mortar Model Underscore Undervalued Buy Thesis
- LifeStance Health Guides 2026 Growth, Announces Buyback Program